Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase II for Neurofibromatoses Type I (Von Recklinghausen’s Disease). According to GlobalData, Phase II drugs for Neurofibromatoses Type I (Von Recklinghausen’s Disease) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tunlametinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tunlametinib (HL-085) is under development for the treatment of advanced solid tumors with BRAF V600 mutation, metastatic colorectal cancer, neurofibromatoses type I mutant plexiform neurofibroma, non-small cell lung cancer and NRAS mutant advanced melanoma. It is formulated as the capsule and administered through oral route. The drug candidate acts by targeting dual specificity mitogen-activated protein kinase kinase 1 (MEK1).
Binjiang Pharma overview
Binjiang Pharma is a biopharmaceutical company. It offers drug discovery, process development and customized services. The company, together with its partners develops targeted small molecule drugs, which has competitive advantages over the existing therapies. Binjiang Pharma is headquartered in Tianjin, China.
For a complete picture of Tunlametinib’s drug-specific PTSR and LoA scores, buy the report here.